• News
  • SAN DIEGO
  • BioTech

Sanofi, Isis win FDA advisers' support for cholesterol treatment

Sanofi and San Diego-based Isis Pharmaceuticals Inc. (Nasdaq: ISIS) won the support of U.S. regulatory advisers for its drug that treats a hyper form of high cholesterol in people with a rare genetic disease.

To continue reading, subscribe now
or
log in to your account
User Response
0 UserComments

Isis Pharmaceuticals Inc.

Company Website

1896 Rutherford Road
Carlsbad, CA 92008

Company Trade Data

Stock Symbol Close
Change
Chg %Chg
Volume
52-Week
High Low
ISIS
63.18
  -0.49  
- 0.77%
2,719,856,000
77.80
22.25

Insider Trade Data

Date Insider Shares Type Value
03/24/2015 Bennett, C Frank 15,000 Sell $1,059,110
03/24/2015 Bennett, C Frank 15,000 Exchange $217,050
03/24/2015 Bennett, C Frank 15,000 Sell $1,059,110
03/24/2015 Bennett, C Frank 15,000 Exchange $217,050
03/05/2015 Geary, Richard S 18,095 Sell $1,287,383

Isis Pharmaceuticals Inc. Executive(s):

Stanley Crooke

  • Chief Executive Officer, Founder, President, Chairman

Similar Companies

NAICS - 325414 - Biological Product (except Diagnostic) Manufacturing
SIC - 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES
Subscribe Today!